Search

Your search keyword '"Kim, Min Kyoung"' showing total 15 results
Start Over Author "Kim, Min Kyoung" Journal journal of korean medical science
15 results on '"Kim, Min Kyoung"'

2. Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea

Author

Kim, Jin Seok, primary, Jang, Jun Ho, additional, Jo, Deog-Yeon, additional, Ahn, Seo-Yeon, additional, Yoon, Sung-Soo, additional, Lee, Je-Hwan, additional, Kim, Sung-Hyun, additional, Choi, Chul Won, additional, Shin, Ho-Jin, additional, Kim, Min-Kyoung, additional, Lee, Jae Hoon, additional, Mun, Yeung-Chul, additional, Kong, Jee Hyun, additional, Hyun, BokJin, additional, Nam, HyunSun, additional, Kim, Eunhye, additional, Kwak, Min Joo, additional, Won, Yong Kyun, additional, and Lee, Jong Wook, additional

Published
2023
Full Text
View/download PDF

3. Correlation between Morphologic Grading and Euploidy Rates of Blastocysts, and Clinical Outcomes in In Vitro Fertilization Preimplantation Genetic Screening

Author

Kim, Min Kyoung, primary, Park, Jae Kyun, additional, Jeon, Yunmi, additional, Choe, Seung-Ah, additional, Lee, Hee Jun, additional, Kim, Jayeon, additional, Chang, Eun Mi, additional, Kim, Ji Won, additional, Lyu, Sang Woo, additional, Kim, Jin Young, additional, Kwak, In Pyung, additional, Lee, Woo Sik, additional, and Yoon, Tae Ki, additional

Published
2019
Full Text
View/download PDF

6. Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea

Author

Kim, Soo-Jeong, primary, Cheong, June-Won, additional, Min, Yoo Hong, additional, Choi, Young Jin, additional, Lee, Dong-Gun, additional, Lee, Je-Hwan, additional, Yang, Deok-Hwan, additional, Lee, Sang Min, additional, Kim, Sung-Hyun, additional, Kim, Yang Soo, additional, Kwak, Jae-Yong, additional, Park, Jinny, additional, Kim, Jin Young, additional, Kim, Hoon-Gu, additional, Kim, Byung Soo, additional, Ryoo, Hun-Mo, additional, Jang, Jun Ho, additional, Kim, Min Kyoung, additional, Kang, Hye Jin, additional, Cho, In Sung, additional, Mun, Yeung Chul, additional, Jo, Deog-Yeon, additional, Kim, Ho Young, additional, Park, Byeong-Bae, additional, and Kim, Jin Seok, additional

Published
2014
Full Text
View/download PDF

13. Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study

Author

Baek, Jin Ho, primary, Kim, Jong Gwang, additional, Sohn, Sang Kyun, additional, Kim, Dong Hwan, additional, Lee, Kyu Bo, additional, Song, Hong Suk, additional, Kwon, Ki Young, additional, Do, Young Rok, additional, Ryoo, Hun Mo, additional, Bae, Sung Hwa, additional, Park, Keon Uk, additional, Kim, Min Kyoung, additional, Lee, Kyung Hee, additional, Hyun, Myung Soo, additional, Chung, Ho Young, additional, and Yu, Wansik, additional

Published
2005
Full Text
View/download PDF

14. Erratum: Correction of Affiliations in the Article "Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study".

Author

Lee JM, Choi JY, Hong KT, Kang HJ, Shin HY, Baek HJ, Kook H, Kim S, Lee JW, Chung NG, Cho B, Cho SG, Park KM, Yang EJ, Lim YT, Suh JK, Kang SH, Kim H, Koh KN, Im HJ, Seo JJ, Cho HW, Ju HY, Lee JW, Yoo KH, Sung KW, Koo HH, Park KD, Hah JO, Kim MK, Han JW, Hahn SM, Lyu CJ, Shim YJ, Kim HS, Do YR, Yoo JW, Lim YJ, Jeon IS, Chueh HW, Oh SY, Choi HS, Park JE, Lee JA, Park HJ, Park BK, Kim SK, Lim JY, Park ES, Park SK, Choi EJ, Choi YB, and Yoon JH

Abstract

This corrects the article on p. e393 in vol. 35, PMID: 33258329., (© 2021 The Korean Academy of Medical Sciences.)

Published
2021
Full Text
View/download PDF

15. Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study.

Author

Lee JM, Choi JY, Hong KT, Kang HJ, Shin HY, Baek HJ, Kook H, Kim S, Lee JW, Chung NG, Cho B, Cho SG, Park KM, Yang EJ, Lim YT, Suh JK, Kang SH, Kim H, Koh KN, Im HJ, Seo JJ, Cho HW, Ju HY, Lee JW, Yoo KH, Sung KW, Koo HH, Park KD, Hah JO, Kim MK, Han JW, Hahn SM, Lyu CJ, Shim YJ, Kim HS, Do YR, Yoo JW, Lim YJ, Jeon IS, Chueh HW, Oh SY, Choi HS, Park JE, Lee JA, Park HJ, Park BK, Kim SK, Lim JY, Park ES, Park SK, Choi EJ, Choi YB, and Yoon JH

Subjects
Adolescent, Antineoplastic Agents adverse effects, Bleomycin adverse effects, Bleomycin therapeutic use, Child, Child, Preschool, Doxorubicin adverse effects, Doxorubicin therapeutic use, Endocrine System Diseases etiology, Female, Hematopoietic Stem Cell Transplantation, Hodgkin Disease mortality, Hodgkin Disease pathology, Humans, Infant, Infant, Newborn, Male, Republic of Korea, Retrospective Studies, Survival Rate, Treatment Outcome, Vinblastine adverse effects, Vinblastine therapeutic use, Young Adult, Antineoplastic Agents therapeutic use, Hodgkin Disease drug therapy
Abstract

Background: Hodgkin's lymphoma (HL) constitutes 10%-20% of all malignant lymphomas and has a high cure rate (5-year survival, around 90%). Recently, interest has increased concerning preventing secondary complications (secondary cancer, endocrine disorders) in long-term survivors. We aimed to study the epidemiologic features and therapeutic outcomes of HL in children, adolescents, and young adults in Korea., Methods: We performed a multicenter, retrospective study of 224 patients aged < 25 years diagnosed with HL at 22 participating institutes in Korea from January 2007 to August 2016., Results: A higher percentage of males was diagnosed at a younger age. Nodular sclerosis histopathological HL subtype was most common, followed by mixed cellularity subtype. Eighty-one (36.2%), 101 (45.1%), and 42 (18.8%) patients were classified into low, intermediate, and high-risk groups, respectively. Doxorubicin, bleomycin, vinblastine, dacarbazine was the most common protocol (n = 102, 45.5%). Event-free survival rate was 86.0% ± 2.4%, while five-year overall survival (OS) rate was 96.1% ± 1.4%: 98.7% ± 1.3%, 97.7% ± 1.6%, and 86.5% ± 5.6% in the low, intermediate, and high-risk groups, respectively ( P = 0.021). Five-year OS was worse in patients with B-symptoms, stage IV disease, high-risk, splenic involvement, extra-nodal lymphoma, and elevated lactate dehydrogenase level. In multivariate analysis, B-symptoms and extra-nodal involvement were prognostic factors for poor OS. Late complications of endocrine disorders and secondary malignancy were observed in 17 and 6 patients, respectively., Conclusion: This is the first study on the epidemiology and treatment outcomes of HL in children, adolescents, and young adults in Korea. Future prospective studies are indicated to develop therapies that minimize treatment toxicity while maximizing cure rates in children, adolescents, and young adults with HL., Competing Interests: The authors have no potential conflicts of interest to disclose., (© 2020 The Korean Academy of Medical Sciences.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results